Changes in Beneficial Ownership · 4
Dianthus Therapeutics, Inc.
DNTHNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-17
- Issuer
- Dianthus Therapeutics, Inc. /DE/
- Issuer CIK
- 0001690585
- Trading symbol
- DNTH
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- CARR EDWARD
- Reporting owner CIK
- 0001273351
- Relationship
- Officer
- Officer title
- CHIEF ACCOUNTING OFFICER
- Address
- C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-17 | M · Form 4[F1] | 20,000 | A | 17.88 | 20,000 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 7,928 | D | 100.43[F2] | 12,072 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 6,771 | D | 101.37[F3] | 5,301 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 3,501 | D | 102.39[F4] | 1,800 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 1,100 | D | 103.20[F5] | 700 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 700 | D | 104.39[F6] | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 17.88 | 2026-09-17 | M · Form 4[F1] | 20,000 | D | 0 | [F7] | 2034-01-23 | Common Stock | 20,000 | 43,818 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7
- F2
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.98 to $100.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F3
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.99 to $101.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F4
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.99 to $102.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F5
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.05 to $103.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F6
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.17 to $104.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F7
- The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Adam Veness, as attorney-in-fact for Edward Carr
- Date
- 2026-09-18
Company context
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.